Frontiers | S100A8/A9 in Inflammation
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01298/full
WebS100A8, S100A9, and S100A8/A9 have been demonstrated to modulate production of pro-inflammatory mediators, including cytokines, chemokines, ROS, and NO. S100A8, in vitro , reduces mast cell degranulation and secretion of IL-4, IL-6, and GM-CSF in response to IgE-crosslinking by inhibiting intracellular ROS production.
DA: 1 PA: 56 MOZ Rank: 13